MET and cancer: Studies have shown that inhibition of the kinase activity of cellular mesenchymal epithelial transition factor (c-Met) can restore the sensitivity of EGFR T790M mutant cancer cells to EGFR TK inhibitors, thereby overcoming the problem of drug resistance [15,16].